The currently marketed SGLT2 inhibitors include dapagliflozin, empagliflozin, canagliflozin, ertugliflozin, ipragliflozin, tofogliflozin, etc. Apart from lowering blood glucose, dapagliflozin has recently been shown to have positive effects on patients with heart failure (McMurray et al., 2019). The gene discussed is SLC5A2; the disease is heart failure.